FDA knocks down Enzyvant candidate on manufacturing concerns after plant inspection

Privately held biotech Enzyvant was hoping its first shot at an FDA approval with a rare immunodeficiency disease candidate would come up in its favor. But the FDA has dashed those hopes, citing manufacturing concerns in a response letter—at least, for now.